The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ofatumumab in combination with high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
Januario E. Castro
No relevant relationships to disclose
Michael Y. Choi
No relevant relationships to disclose
Tomas Carvajal
No relevant relationships to disclose
Hongying Li
No relevant relationships to disclose
Danelle Frances James
No relevant relationships to disclose
Karen Messer
No relevant relationships to disclose
Thomas J. Kipps
No relevant relationships to disclose